O	0	12	Personalized
O	13	23	Prediction
O	24	26	of
B-Disease	27	35	Glaucoma
O	36	47	Progression
O	48	53	Under
O	54	63	Different
O	64	70	Target
B-Characteristic	71	82	Intraocular
I-Characteristic	83	91	Pressure
I-Characteristic	92	98	Levels
O	99	104	Using
B-Diagnostic_tool	105	113	Filtered
I-Diagnostic_tool	114	125	Forecasting
I-Diagnostic_tool	126	133	Methods
O	133	134	.

O	136	138	To
O	139	147	generate
O	148	160	personalized
O	161	170	forecasts
O	171	173	of
O	174	177	how
O	178	186	patients
O	187	191	with
B-Disease	192	196	open
I-Disease	196	197	-
I-Disease	197	202	angle
I-Disease	203	211	glaucoma
O	212	213	(
B-Disease	213	216	OAG
O	216	217	)
O	218	228	experience
O	229	236	disease
O	237	248	progression
O	249	251	at
O	252	261	different
B-Characteristic	262	273	intraocular
I-Characteristic	274	282	pressure
O	283	284	(
B-Characteristic	284	287	IOP
O	287	288	)
O	289	295	levels
O	296	298	to
O	299	302	aid
O	303	313	clinicians
O	314	318	with
O	319	326	setting
O	327	339	personalized
O	340	346	target
B-Characteristic	347	351	IOPs
O	351	352	.

O	353	362	Secondary
O	363	371	analyses
O	372	377	using
O	378	390	longitudinal
O	391	395	data
O	396	400	from
O	401	402	2
O	403	413	randomized
O	414	424	controlled
O	425	431	trials
O	431	432	.

O	433	445	Participants
O	446	450	with
B-Disease	451	459	moderate
I-Disease	460	462	or
I-Disease	463	471	advanced
I-Disease	472	475	OAG
O	476	480	from
O	481	484	the
O	485	498	Collaborative
O	499	506	Initial
B-Disease	507	515	Glaucoma
O	516	525	Treatment
O	526	531	Study
O	532	533	(
O	533	538	CIGTS
O	538	539	)
O	540	542	or
O	543	546	the
B-Disease	547	555	Advanced
I-Disease	556	564	Glaucoma
O	565	577	Intervention
O	578	583	Study
O	584	585	(
O	585	589	AGIS
O	589	590	)
O	590	591	.

O	592	594	By
O	595	600	using
O	601	611	perimetric
O	612	615	and
O	616	626	tonometric
O	627	631	data
O	632	636	from
O	637	642	trial
O	643	655	participants
O	655	656	,
O	657	659	we
O	660	669	developed
O	670	673	and
O	674	683	validated
O	684	690	Kalman
O	691	697	Filter
O	698	699	(
O	699	701	KF
O	701	702	)
O	703	709	models
O	710	713	for
O	714	718	fast
O	718	719	-
O	719	720	,
O	721	725	slow
O	725	726	-
O	726	727	,
O	728	731	and
O	732	746	nonprogressing
O	747	755	patients
O	756	760	with
B-Disease	761	764	OAG
O	764	765	.

O	766	769	The
O	770	772	KF
O	773	776	can
O	777	785	generate
O	786	798	personalized
O	799	802	and
O	803	814	dynamically
O	815	822	updated
O	823	832	forecasts
O	833	835	of
B-Disease	836	839	OAG
O	840	851	progression
O	852	857	under
O	858	867	different
O	868	874	target
B-Characteristic	875	878	IOP
O	879	885	levels
O	885	886	.

O	887	890	For
O	891	895	each
O	896	907	participant
O	907	908	,
O	909	911	we
O	912	922	determined
O	923	926	how
O	927	931	mean
O	932	941	deviation
O	942	943	(
O	943	945	MD
O	945	946	)
O	947	952	would
O	953	959	change
O	960	962	if
O	963	966	the
O	967	974	patient
O	975	984	maintains
O	985	988	his
O	988	989	/
O	989	992	her
B-Characteristic	993	996	IOP
O	997	999	at
O	1000	1001	1
O	1002	1004	of
O	1005	1006	7
O	1007	1013	levels
O	1014	1015	(
O	1015	1016	6
O	1016	1017	,
O	1018	1019	9
O	1019	1020	,
O	1021	1023	12
O	1023	1024	,
O	1025	1027	15
O	1027	1028	,
O	1029	1031	18
O	1031	1032	,
O	1033	1035	21
O	1035	1036	,
O	1037	1039	or
O	1040	1042	24
O	1043	1047	mmHg
O	1047	1048	)
O	1049	1053	over
O	1054	1057	the
O	1058	1062	next
O	1063	1064	5
O	1065	1070	years
O	1070	1071	.

O	1072	1074	We
O	1075	1079	also
O	1080	1085	model
O	1086	1089	and
O	1090	1097	predict
O	1098	1105	changes
O	1106	1108	to
O	1109	1111	MD
O	1112	1116	over
O	1117	1120	the
O	1121	1125	same
O	1126	1130	time
O	1131	1138	horizon
O	1139	1141	if
B-Characteristic	1142	1145	IOP
O	1146	1148	is
O	1149	1158	increased
O	1159	1161	or
O	1162	1171	decreased
O	1172	1174	by
O	1175	1176	3
O	1176	1177	,
O	1178	1179	6
O	1179	1180	,
O	1181	1184	and
O	1185	1186	9
O	1187	1191	mmHg
O	1192	1196	from
O	1197	1200	the
O	1201	1206	level
O	1207	1215	attained
O	1216	1218	in
O	1219	1222	the
O	1223	1229	trials
O	1229	1230	.

O	1231	1243	Personalized
O	1244	1253	estimates
O	1254	1256	of
O	1257	1260	the
O	1261	1267	change
O	1268	1270	in
O	1271	1273	MD
O	1274	1279	under
O	1280	1289	different
O	1290	1296	target
B-Characteristic	1297	1300	IOP
O	1301	1307	levels
O	1307	1308	.

O	1309	1310	A
O	1311	1316	total
O	1317	1319	of
O	1320	1323	571
O	1324	1336	participants
O	1337	1338	(
O	1338	1342	mean
O	1343	1346	age
O	1346	1347	,
O	1348	1350	64
O	1350	1351	.
O	1351	1352	2
O	1353	1358	years
O	1358	1359	;
O	1360	1368	standard
O	1369	1378	deviation
O	1378	1379	,
O	1380	1382	10
O	1382	1383	.
O	1383	1384	9
O	1384	1385	)
O	1386	1390	were
O	1391	1399	followed
O	1400	1403	for
O	1404	1405	a
O	1406	1410	mean
O	1411	1413	of
O	1414	1415	6
O	1415	1416	.
O	1416	1417	5
O	1418	1423	years
O	1424	1425	(
O	1425	1433	standard
O	1434	1443	deviation
O	1443	1444	,
O	1445	1446	2
O	1446	1447	.
O	1447	1448	8
O	1448	1449	)
O	1449	1450	.

O	1451	1454	Our
O	1455	1461	models
O	1462	1471	predicted
O	1472	1476	that
O	1476	1477	,
O	1478	1480	on
O	1481	1488	average
O	1488	1489	,
O	1490	1494	fast
O	1495	1506	progressors
O	1507	1512	would
O	1513	1517	lose
O	1518	1519	2
O	1519	1520	.
O	1520	1521	1
O	1521	1522	,
O	1523	1524	6
O	1524	1525	.
O	1525	1526	7
O	1526	1527	,
O	1528	1531	and
O	1532	1534	11
O	1534	1535	.
O	1535	1536	2
O	1537	1545	decibels
O	1546	1547	(
O	1547	1549	dB
O	1549	1550	)
O	1551	1553	MD
O	1554	1559	under
O	1560	1566	target
B-Characteristic	1567	1571	IOPs
O	1572	1574	of
O	1575	1576	6
O	1576	1577	,
O	1578	1580	15
O	1580	1581	,
O	1582	1585	and
O	1586	1588	24
O	1589	1593	mmHg
O	1593	1594	,
O	1595	1607	respectively
O	1607	1608	,
O	1609	1613	over
O	1614	1615	5
O	1616	1621	years
O	1621	1622	.

O	1623	1625	In
O	1626	1634	contrast
O	1634	1635	,
O	1636	1638	on
O	1639	1646	average
O	1646	1647	,
O	1648	1652	slow
O	1653	1664	progressors
O	1665	1670	would
O	1671	1675	lose
O	1676	1677	0
O	1677	1678	.
O	1678	1679	8
O	1679	1680	,
O	1681	1682	2
O	1682	1683	.
O	1683	1684	1
O	1684	1685	,
O	1686	1689	and
O	1690	1691	4
O	1691	1692	.
O	1692	1693	1
O	1694	1696	dB
O	1697	1699	MD
O	1700	1705	under
O	1706	1709	the
O	1710	1714	same
O	1715	1721	target
B-Characteristic	1722	1726	IOPs
O	1727	1730	and
O	1731	1735	time
O	1736	1741	frame
O	1741	1742	.

O	1743	1747	When
O	1748	1753	using
O	1754	1757	our
O	1758	1762	tool
O	1763	1765	to
O	1766	1774	quantify
O	1775	1778	the
B-Disease	1779	1782	OAG
O	1783	1794	progression
O	1795	1803	dynamics
O	1804	1807	for
O	1808	1811	all
O	1812	1815	571
O	1816	1824	patients
O	1824	1825	,
O	1826	1828	we
O	1829	1834	found
O	1835	1837	no
O	1838	1851	statistically
O	1852	1863	significant
O	1864	1875	differences
O	1876	1880	over
O	1881	1882	5
O	1883	1888	years
O	1889	1896	between
O	1897	1908	progression
O	1909	1912	for
B-Characteristic	1913	1918	black
I-Characteristic	1919	1925	versus
I-Characteristic	1926	1931	white
O	1931	1932	,
B-Characteristic	1933	1937	male
I-Characteristic	1938	1944	versus
I-Characteristic	1945	1951	female
O	1951	1952	,
O	1953	1956	and
O	1957	1962	CIGTS
O	1963	1969	versus
O	1970	1974	AGIS
O	1975	1987	participants
O	1988	1993	under
O	1994	2003	different
O	2004	2010	target
B-Characteristic	2011	2015	IOPs
O	2016	2017	(
O	2017	2018	P
O	2020	2021	>
O	2023	2024	0
O	2024	2025	.
O	2025	2027	05
O	2028	2031	for
O	2032	2035	all
O	2035	2036	)
O	2036	2037	.

O	2038	2040	To
O	2041	2044	our
O	2045	2054	knowledge
O	2054	2055	,
O	2056	2060	this
O	2061	2063	is
O	2064	2067	the
O	2068	2073	first
O	2074	2082	clinical
O	2083	2091	decision
O	2091	2092	-
O	2092	2098	making
O	2099	2103	tool
O	2104	2108	that
O	2109	2118	generates
O	2119	2131	personalized
O	2132	2141	forecasts
O	2142	2144	of
O	2145	2148	the
O	2149	2159	trajectory
O	2160	2162	of
B-Disease	2163	2166	OAG
O	2167	2178	progression
O	2179	2181	at
O	2182	2191	different
O	2192	2198	target
B-Characteristic	2199	2202	IOP
O	2203	2209	levels
O	2209	2210	.

O	2211	2215	This
O	2216	2224	approach
O	2225	2228	can
O	2229	2233	help
O	2234	2244	clinicians
O	2245	2254	determine
O	2255	2266	appropriate
O	2266	2267	,
O	2268	2280	personalized
O	2281	2287	target
B-Characteristic	2288	2292	IOPs
O	2293	2296	for
O	2297	2305	patients
O	2306	2310	with
B-Disease	2311	2314	OAG
O	2314	2315	.
